1 / 4

The HPTN 052 HIV Treatment as Prevention Trial:

The HPTN 052 HIV Treatment as Prevention Trial: A case study of ethical considerations in human research conducted in low and middle income countries (LMIC). Dr. Philip Berger St. Michael ’ s Hospital, Toronto, Canada.

jaxon
Télécharger la présentation

The HPTN 052 HIV Treatment as Prevention Trial:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The HPTN 052 HIV Treatmentas Prevention Trial: A case study of ethical considerations in human research conducted in low and middle income countries (LMIC) Dr. Philip Berger St. Michael’s Hospital, Toronto, Canada

  2. The HPTN 052 HIV Treatment as Prevention Trial: a case study of the ethical considerations in human research conducted in low and middle income countries (LMIC) Discussion • “Delayed therapy” group were not treated in accordance with existing country and international guidelines. • Ethical guidelines -- current standard of treatment should be provided to clinical trial subjects. • ARV coverage rates were sufficiently high (approaching or exceeding the 80% UNAIDS definition of universal coverage) • The absence of treatment infrastructure was not a bone fide reason to withhold treatment • The 052 descriptor “early” is inaccurate relative to standard ARV initiation guidelines in the USA.

More Related